Our client Amgen Presents New Data On Talimogene Laherparepvec As Single Agent And Combination Therapy In Metastatic Melanoma At ASCO
Phase 1 Study Evaluating Talimogene Laherparepvec Plus Ipilimumab Showed Tolerability at Doses Administered Tumors Shrank in Size or Were No Longer Detectable in 56 Percent of Patients Positive Overall Survival Trend Observed in Phase 3 Study
THOUSAND OAKS, Calif., June 2, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from two key clinical trials that support the potential of talimogene laherparepvec, or Tvec, a novel, investigational oncolytic immunotherapy, as both a single agent and as part of a combination regimen in patients with metastatic melanoma. The findings were presented at the 50th Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) in Chicago.
- 0 Comments
- Topic: Healthcare, Pharma, news
